## Combining two cytotoxic agents with continuous dose levels in phase I-II clinical trials
### Authors: José L. Jiménez (jose_luis.jimenez@novartis.com) and Mourad Tighiouart (mourad.tighiouart@cshs.org)

In this article, we propose a design for phase I-II clinical trials that combine two cytotoxic agents with continuous dose levels. 
